Guangzhou Wondfo Biotech Co.,Ltd. (300482.SZ) released its interim report for the first half of 2025, showing operating revenue of 1.246 billion yuan, representing a year-over-year decrease of 20.92%. Net profit attributable to shareholders of the listed company reached 189 million yuan, declining 46.82% compared to the same period last year. Net profit attributable to shareholders excluding non-recurring gains and losses totaled 154 million yuan, down 52.73% year-over-year. Basic earnings per share stood at 0.39 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments